-
公开(公告)号：EP0772448A1
公开(公告)日：1997-05-14
申请号：EP96919253.0
申请日：1996-06-06
CPC分类号： C07K14/635 , A61K38/00
摘要： Cyclic analogs of PTH and PTHrP wherein a disulfide or amide bond links the side chains of residues A13 and A17, A26 and A30, or A13 and A17 and A26 and A30.
-
公开(公告)号：EP0753066A1
公开(公告)日：1997-01-15
申请号：EP94925680.0
申请日：1994-07-22
发明人： O'DONNELL, Michael, A. , DUDA, Rosemary, B. , DeWOLF, William, C. , ALDOVINI, Anna , YOUNG, Richard, A. , MURRAY, Peter, J.
CPC分类号： A61K39/04 , A61K38/00 , A61K39/00 , C07K14/005 , C07K14/35 , C07K14/52 , C07K14/55 , C12N15/74 , C12N15/87 , C12N2740/16022 , C12N2740/16122 , C12N2740/16222 , C12R1/32 , Y10S435/863 , Y10S435/864 , Y10S435/865 , Y10S435/866
摘要： The present invention relates to genetically recombinant (genetically engineered) mycobacteria which express DNA of interest which has been incorporated into the mycobacteria and is expressed extrachromosomally (episomally or autonomously) in the recombinant mycobacteria under the control of a promoter. It particularly relates to recombinant M. bovis-BCG in which DNA of interest is expressed extrachromosomally under the control of a mycobacterial hsp promoter, such as hsp70 and hsp60. DNA of interest is defined herein as heterologous DNA (i.e., DNA from a source other than the mycobacterium into which it is introduced) and is all or a portion of a gene or genes encoding enzymes, cytokines, lymphokines and immunopotentiators.
-
公开(公告)号：EP0630384A4
公开(公告)日：1996-09-04
申请号：EP93907073
申请日：1993-03-01
IPC分类号： C12N15/09 , A61K31/70 , A61K38/00 , A61K48/00 , A61P37/06 , C07H21/04 , C07K14/47 , C07K14/495 , C07K14/52 , C07K14/54 , C07K14/705 , C07K14/715 , C07K15/00 , C07H15/12
CPC分类号： C07K14/54 , A61K38/00 , A61K48/00 , C07K14/4703 , C07K14/4713 , C07K14/495
摘要： Disclosed is a method of preventing graft rejection by inducing a state of local immunosuppression at the transplant site with expression of recombinant proteins by the allograft. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65 DEG C for 15 minutes, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.
-
公开(公告)号：EP0489108B1
公开(公告)日：1996-03-13
申请号：EP90913638.4
申请日：1990-08-15
IPC分类号： A61K31/445 , A61K31/475
CPC分类号： A61K45/06 , A61K8/492 , A61K31/00 , A61K31/415 , A61K31/475 , A61Q7/00
摘要： A method and composition for the topical treatment of cutaneous, mucosal or ocular hypersensitivity reactions, inflammation, or epithelial hyperproliferative states, including those associated with scarring. The composition, to be applied directly to an affected area of the skin, eye, or mucosal membrane, consists of a therapeutic amount of reserpine, spiperone, or other serotonin antagonist which has been incorporated into a vehicle suitable for topical administration.
-
公开(公告)号：EP0655919A1
公开(公告)日：1995-06-07
申请号：EP93920283.0
申请日：1993-08-23
CPC分类号： A61K31/47
摘要： Treatment of cells or humans carrying or infected with a virus capable of causing an immunodeficiency disease with compounds of formula (I), wherein R, R1 and R2 are each independently selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, noncyclic heteroalkyl, and substituted and unsubstituted alkenyl, provided at least two of the substituents of R, R1 and R2 are other than hydrogen.
-
公开(公告)号：EP0630383A1
公开(公告)日：1994-12-28
申请号：EP93906174.0
申请日：1993-02-24
申请人： BRIGHAM AND WOMEN'S HOSPITAL , Beth Israel Hospital Association , SERAGEN, INC. , BACH, Jean-François
CPC分类号： C07K14/55 , A61K38/164 , A61K47/642 , C07K14/34 , C07K2319/55 , C07K2319/75 , Y10S514/866
摘要： L'invention se rapporte à un procédé visant à traiter un patient atteint de diabétes et qui consiste à administrer audit patient une molécule hybride contenant une cytoxine réunie de façon covalente à l'interleukine 2, molécule qui est capable de se lier au récepteur de l'interleukine 2 sur une cellule contribuant à l'état de la maladie et qui est également capable de diminuer la viabilité de cette cellule.
-
57.发明公开USE OF SPIPERONE OR SPIPERONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS. 失效使用和螺哌SPIPERONDERIVATEN作为免疫抑制剂。
公开(公告)号：EP0661972A4
公开(公告)日：1994-10-27
申请号：EP93902752
申请日：1992-12-23
申请人： BETH ISRAEL HOSPITAL
发明人： SHARPE RICHARD J , ARNDT KENNETH A , GALLI STEPHEN J , MELTZER PETER C , RAZDAN RAJ K , SARD HOWARD P
IPC分类号： C07D471/20 , A61K31/435 , A61P37/06 , A61K31/44
CPC分类号： A61K31/435
-
58.发明公开SYNTHESIS OF FULL-LENGTH, DOUBLE-STRANDED DNA FROM A SINGLE-STRANDED LINEAR DNA TEMPLATE 失效从单条线性DNA模板合成全长双链DNA
公开(公告)号：EP0567587A1
公开(公告)日：1993-11-03
申请号：EP92905280.0
申请日：1992-01-14
CPC分类号： C12N15/1096 , C12Q1/6855 , C12Q2525/173
摘要： Procédé de préparation d'un ADN double brin à partir d'une matrice d'ADN simple brin, le procédé consistant à: a) prendre un premier brin d'ADN; b) ajouter une queue d'oligonucléotide homopolymère à l'extrémité 3' du premier brin d'ADN pour produire un premier brin d'ADN à queue; c) prendre une amorce d'oligonucléotide homopolymère simple brin complémentaire à une partie de la queue; d) mettre en contact l'amorce avec le premier brin d'ADN à queue; e) synthétiser, en présence de l'amorce et du premier brin d'ADN à queue, un second brin d'ADN complémentaire au premier brin d'ADN; et f) enlever la queue et l'amorce respectivement, des premier et second brins d'ADN à condition que la queue et/ou l'amorce contienne(nt) de l'ARN.
摘要翻译： 一种从单链DNA模板制备双链DNA的方法，该方法包括：a）取第一链DNA; b）向第一链DNA的3'末端添加均聚物寡核苷酸尾以产生第一链尾DNA; c）获取与尾部的一部分互补的单链均聚物寡核苷酸引物; d）使引物与第一链尾DNA接触; e）在引物和尾DNA的第一链存在下合成与第一链DNA互补的DNA的第二链; 和f）分别除去DNA的第一和第二链的尾部和引物，条件是尾部和/或引物含有RNA。
-
公开(公告)号：EP0495014A4
公开(公告)日：1993-07-28
申请号：EP91901910
申请日：1990-10-04
发明人： FOSSEL, ERIC, T.
IPC分类号： A61K35/14 , A61K38/00 , A61K38/17 , A61K38/44 , A61M1/36 , A61P31/12 , A61P35/00 , C07K14/00 , C07K14/775 , C12P7/12 , C07J9/00 , C12P21/00 , C12P33/06
CPC分类号： A61K31/185 , A61K31/02 , A61K31/366 , A61K31/727 , A61K33/00 , A61K35/14 , A61K38/00 , C07K14/775 , A61K2300/00
摘要： Methods and apparatuses are disclosed for preparing novel oxidized lipoprotein compositions. Peroxides are capable of generating free-radicals which, in turn, can oxidize lipoproteins in vitro or in vivo. It has been discovered that hydrogen peroxide itself or in conjunction with certain enzymes such as peroxidase or lipoxidase can oxidize lipoproteins. Peroxidized low density lipoproteins are the most preferred composition. Oxidized lipoproteins exhibit a cytotoxic effect to which diseased cells which are more susceptible than healthy cells. Thus, oxidized lipoproteins may be useful in treating many disease states. The extent of lipoprotein peroxidation is measured by obtaining a C-13 NMR spectrum of the oxidized lipoprotein solution.
-
60.发明公开
公开(公告)号：EP0494992A4
公开(公告)日：1993-03-31
申请号：EP90916422
申请日：1990-10-04
发明人： FOSSEL, ERIC, T.
IPC分类号： A61K35/14 , A61K38/00 , A61K38/17 , A61K38/44 , A61M1/36 , A61P31/12 , A61P35/00 , C07K14/00 , C07K14/775 , A61K37/00 , C07K5/00 , C09F5/06
CPC分类号： A61K31/185 , A61K31/02 , A61K31/366 , A61K31/727 , A61K33/00 , A61K35/14 , A61K38/00 , C07K14/775 , A61K2300/00
摘要： Methods and apparatuses are disclosed for preparing novel oxidized lipoprotein compositions. Peroxides are capable of generating free-radicals which, in turn, can oxidize lipoproteins in vitro or in vivo. It has been discovered that hydrogen peroxide itself or in conjunction with certain enzymes such as peroxidase or lipoxidase can oxidize lipoproteins. Peroxidized low density lipoproteins are the most preferred composition. Oxidized lipoproteins exhibit a cytotoxic effect to which diseased cells which are more susceptible than healthy cells. Thus, oxidized lipoproteins may be useful in treating many disease states. The extent of lipoprotein peroxidation is measured by obtaining a C-13 NMR spectrum of the oxidized lipoprotein solution.
-
-
-
-
-
-
-
-
-
搜索结果
163 条记录 (耗时 0.022 秒)
